** Citi says investor confidence for biopharmaceutical firm Telix Pharmaceuticals TLX.AX hinges on FDA resubmission of Pixclara, and the safety data from Phase 3 ProstACT Global trial for TLX591

** Pixclara is a brain cancer imaging agent, while TLX591 is a prostate cancer drug candidate

** Brokerage believes best-case scenarios for both events - Class 1 submission for Pixclara and perfect commentary on 591, not needed for investors to "warm up to the stock"

** Class 1 resubmission to FDA is subject to a two-month review cycle

** Brokerage expects both events in 2H, estimating Class 2 submission for Pixclara, which entails longer six-month review period

** Citi views the 30-patient safety run-in setup as favourable from a design perspective for 591, even if its inclusion was FDA-motivated

** All 12 analysts rate the stock "buy" or higher; their median PT is A$27.26 – LSEG data

** YTD, stock down 37.8%

(Reporting by Sherin Sunny in Bengaluru)

((Sherin.Sunny@thomsonreuters.com))